Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Drugs Make Up For Lipitor Patent Expiration: President Umeda of Pfizer
December 20, 2010
- Daiichi Sankyo Prioritizes 1st-in-Class Drugs in R&D: President Nakayama
December 20, 2010
- AZ's Ticagrelor Obtains EC Approval to Prevent Atherothrombotic Events in ACS
December 20, 2010
- Rifaximin to Drive ASKA's Business: President Yamaguchi
December 20, 2010
- BMS Applies for Additional Indication for SPRYCEL in Japan
December 20, 2010
- Sprycel Obtains EC Approval for a New Indication
December 20, 2010
- Novartis Recommends Rasilez for Use in First-Line Therapy
December 20, 2010
- Gov't Aims to Create Japanese Version of NIH
December 20, 2010
- FDA Advisory Committee Recommends Approval of Contrave for Obesity: Takeda
December 20, 2010
- MCHC Aims at Operating Profits of \120 Bil. for Healthcare Business in FY2015
December 20, 2010
- NCGM to Start IIT to Compare 3 Antidiabetic Drugs
December 20, 2010
- Pfizer to Develop Orphan Drugs Even if Profits Are Small: Mr Matsumori
December 20, 2010
- Teijin Pharma, Genzyme Aim at Peak Sales of ¥15 Bil. for Synvisc
December 20, 2010
- Edoxaban Significantly Prevents VTE after THR vs Enoxaparin: Daiichi Sankyo
December 20, 2010
- Generics Dispensing Rate Up to 22.8%: Korosho Survey
December 20, 2010
- Senju to Double Its Share in Glaucoma Market
December 20, 2010
- DSP Announces Results of 3rd PIII Trial of Latuda
December 20, 2010
- 60% of Pharmacies Claim Premiums for Generics Dispensing System: NPhA Survey
December 20, 2010
- Astellas Obtains Oncology Technology Platform from AVEO
December 13, 2010
- Itochu, PRISM BioLab to Market Library of Chemical Compounds
December 13, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…